An interventional study of High intensity interval exercise session and Isometric neuromuscular exercise session in Menopause, Blood Pressure and Cognitive Decline, sponsored by University of Poitiers. Completed at 1 site in France. Open to female participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-01.
Sponsored by University of Poitiers · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Cognitive Dysfunction with a site in France — 52 open to participants now, 60 under way, 6 of them phase 3. Cognitive Dysfunction · France.
Among the 189 studies in Cognitive Dysfunction with a site in France, this one is the 118th largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2023, is one of 104 with no phase, and was the 160th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →52 of the 189 studies in Cognitive Dysfunction with a site in France are open now. Recruiting first, the newest first:
University Hospital, Angers · Sites in France
Ages 60+
Nadine ATTAL · Sites in France
Ages 35–65 · Women only
Aelis Farma · Sites in France, Italy, Spain
Ages 16–32
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 7–20
LNA SANTE · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 45 Years to 65 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 15 · Phase 3 17 · Phase 4 1
First in 2003; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 88 across the 139 interventional studies, 160 across the 50 observational. Of the 110 that completed or were terminated, 12 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 189 have an industry lead sponsor. The 10 most frequent:
University of Poitiers is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
University of Poitiers has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
18 of the studies in Cognitive Dysfunction with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07237009KompanionCare SASEffects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders | 2026-12 |
| NCT07083089Cilcare SASEarly Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR) | 2026-12 |
| NCT07877376Nadine ATTALImpact of Cognitive Impairment on Chronic Pain in Breast Cancer | 2027-01 |
| NCT05790707Poitiers University HospitalEfFect of Ablation of Persistent AtriaL Fibrillation on COgNitive Function in Individuals With Mild Cognitive Impairment | 2027-01 |
Add all 18 to your calendar (.ics) → With an account.
Among the 189 studies in Cognitive Dysfunction with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Menopause is a natural stage in female aging, increasing cardiometabolic risk and making cardio-neuro-vascular disease (CNVD) the leading cause of mortality in women over 60. Declining ovarian hormones are linked to changes in body composition, increased blood pressure, and mild cognitive impairment. Menopause also often involves significant symptoms like menopausal vasomotor symptoms (VMS), affecting 60-80% of women for 5-10 years. Women with VMS exhibit a worse cardiovascular profile and greater cognitive decline.
Physical exercise is a promising non-pharmacological option to reduce CNVD risk and limit cognitive impairment in postmenopausal women, who have a 10-year window post-menopause during which physical activity benefits vascular and possibly neurovascular health. Studies link physical activity to lower cognitive decline and improved quality of life. However, optimal exercise modalities for managing CNVD risk in postmenopausal women remain undetermined.
Menopause is a natural stage in the female aging process, resulting in increased cardiometabolic risk, making cardio-neuro-vascular disease (CNVD) the leading cause of female mortality worldwide after the age of 60. Indeed, falling ovarian hormone concentrations are associated with altered body composition, increased blood pressure, as well as mild cognitive impairment.
For some women, menopause is also accompanied by symptoms that have a significant impact on their quality of life. Among these, menopausal vasomotor symptoms (VMS - hot flushes, night sweats...) are the most frequent, affecting 60% to 80% of women for an average of 5 to 10 years. Several studies have highlighted an altered cardiovascular profile (dyslipidemia, insulin resistance, pre-hypertension/hypertension...) and a more marked decline in cognitive performance in women with VMS.
In order to reduce the risk of CNVD and limit cognitive impairment, physical exercise appears to be a particularly interesting non-pharmacological management option for postmenopausal women. Indeed, the latter seem to present a 10-year post-menopausal time window, during which physical activity has a positive vascular and probably neurovascular effect, although the latter remains to be demonstrated. Numerous studies have also shown that physical activity is associated with a lower rate of cognitive decline, and improved quality of life.
However, to date, there is little evidence to determine which exercise modalities are most effective in managing the risk of CNVD in postmenopausal women.
The aims of this study:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Performed on an ergometer, the intensity of the session is adapted to the participant's physical capacity, initially assessed by the VO2max test at baseline. The session begins with a 5-minute warm-up at 50% of maximum aerobic power (MAP). The exercise then consists of 2 sets of 12 repetitions of 15 seconds each at 100% of MAP and 15 seconds of passive recovery. 2-minute of passive recovery is recommended between the two sets. The session ends with 5-minute of recovery at 50% of MAP.
Other: High intensity interval exercise session
Performed with a handgrip (K-Force grip, KINVENT), the intensity of the session is adapted to the participant's capacity, initially assessed by the isometric maximal voluntary force (MVF) measurement at the beginning of the session. The session consists of 4 repetitions of 2 minutes at 30% of the isometric MVF, separated by 1 minute recovery.
Other: Isometric neuromuscular exercise session
Participants are seated for 30 minutes.
Physical activity session supervised and adapted on ergometer
Physical activity session supervised and adapted with a handgrip
Systolic and diastolic blood pressure (ambulatory blood pressure measurement)
Post-exercise hypotension, using the Mobil-O-Graph (mmHg).
Time frame: After sessions (24 hours)
Systolic and diastolic blood pressure (resting)
Automated oscillometric tensiometer (mmHg).
Time frame: Before and after sessions (15 minutes)
Concentration of cerebral oxygenation
Near-infrared spectroscopy is used to measure concentrations of oxygenated and desoxygenated hemoglobin (µmol/L).
Time frame: Before, during, and after sessions (1 hour)
Working memory
2-back task (scored from 0 to 28, higher scores indicate better working memory).
Time frame: Before and after sessions (10 minutes)
Episodic memory
Memory scale III (MEM-III), a story recall task taken from the test battery in the Wechsler-Memory Scale-Revised (scored from 0 to 25, higher scores indicate better episodic memory).
Time frame: Before and after sessions (15 minutes)
Executive function
Stroop task, used to assess inhibitory control (scored as a ratio, negative score indicates worse inhibitory control vs. positive score indicates better inhibitory control).
Time frame: Before and after sessions (15 minutes)
Perception of exertion
Modified Borg scale (scored 0 to 10, higher score indicates lower exercise tolerance).
Time frame: After sessions (1 minute)
Endothelial function (brachial artery dilation capacity)
At rest, the flow-mediated dilatation technique is used with high-resolution Doppler ultrasound (CX-50 Philipps).
Time frame: Baseline (30 minutes)
Baroreflex sensitivity
At rest, baroreflex sensitivity is measured using the Finapres.
Time frame: Baseline (1 hour)
Aortic systolic and diastolic blood pressure
At rest, using the SphygmoCor device, which measures central blood pressure (mmHg).
Time frame: Baseline (15 minutes)
Arterial stiffness (pulse wave velocity)
At rest, using the SphygmoCor device, which calculates carotid-femoral pulse wave velocity (m/s).
Time frame: Baseline (15 minutes)
Physical fitness
Maximal cardiopulmonary effort test (VO2max).
Time frame: Baseline (30 minutes)
Blood lipid concentrations
Total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (g/L).
Time frame: Baseline (5 minutes)
Blood hormone concentrations
Progesterone, 17-beta-estradiol, and follicle-stimulating hormone (ng/L).
Time frame: Baseline (5 minutes)
Body weight
Total body weight, fat mass, fat-free mass and visceral-fat mass in kilograms using the Tanita impedance scale.
Time frame: Baseline (1 minute)
Body composition
Percentage of body fat and fat-free mass using the Tanita impedance scale.
Time frame: Baseline (1 minute)
Height
Height in meters measured with a height gauge.
Time frame: Baseline (1 minute)
Body mass index
Calculated from total body weight and height (kg/m²).
Time frame: Baseline (1 minute)
Cognitive assessment
Montreal Cognitive Assessment (MoCA) test (scored from 0 to 30, with higher scores indicating better cognitive function).
Time frame: Baseline (15 minutes)
Menopausal rating scale
Composed of 11 items rating the severity of menopausal symptoms from 0 (no symptoms) to 4 (very severe).
Time frame: Baseline (15 minutes)
Hot flash related daily interference scale
Composed of 10 items scored from 0 (no impact) to 10 (completely interferes), evaluating the impact of vasomotor symptoms on daily life.
Time frame: Baseline (15 minutes)
Hospital Anxiety and Depression Scale
It provides two scores ranging from 0 to 21 that quantify anxiety and depression. Higher scores indicate more severe symptoms.
Time frame: Baseline (15 minutes)
Global physical activity questionnaire
Physical activity and sedentary time assessed using the Global Physical Activity Questionnaire. Higher scores indicate better physical activity levels (categorized into high, moderate, and low physical activity levels).
Time frame: Baseline (15 minutes)
Daily tobacco and alcohol use
Use daily or not use.
Time frame: Baseline
Age
Age, age at menarche and menopause (in years).
Time frame: Baseline
Educational level
Secondary education, high school graduate, bachelor's degree, master's or doctoral degree.
Time frame: Baseline
Number of children
Self-reported.
Time frame: Baseline
Plan to share: No
Ran from Mar 2023 to primary completion in Mar 2023, 0 months.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 0 months is below that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Poitiers